FCCC LOGO Faculty Publications
Crawford J , Armitage J , Balducci L , Becker PS , Blayney DW , Cataland SR , Heaney ML , Hudock S , Kloth DD , Kuter DJ , Lyman GH , McMahon B , Rugo HS , Saad AA , Schwartzberg LS , Shayani S , Steensma DP , Talbott M , Vadhan-Raj S , Westervelt P , Westmoreland M , Dwyer M , Ho M
Myeloid Growth Factors
Journal of the National Comprehensive Cancer Network. 2013 Oct;11(10) :1266-1290
PMID: WOS:000325929600010   
Back to previous list
Abstract
Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting
Notes
Crawford, Jeffrey Armitage, James Balducci, Lodovico Becker, Pamela Sue Blayney, Douglas W. Cataland, Spero R. Heaney, Mark L. Hudock, Susan Kloth, Dwight D. Kuter, David J. Lyman, Gary H. McMahon, Brandon Rugo, Hope S. Saad, Ayman A. Schwartzberg, Lee S. Shayani, Sepideh Steensma, David P. Talbott, Mahsa Vadhan-Raj, Saroj Westervelt, Peter Westmoreland, Michael Dwyer, Mary Ho, Maria